From a macro perspective, the "Rani stock forecast" is being supported by rising healthcare investment flows. The Federal Reserve’s dovish stance has eased pressure on growth stocks, making biotech plays like Rani more attractive. Operations: The company generates revenue primarily from its pharmaceuticals segment, amounting to ¥1.20 trillion. More information about Rani Therapeutics can be found on their website at ranitherapeutics.com. Fund managers cite the company’s innovative oral biologics delivery as a reason to maintain a bullish "Rani stock forecast". Patent portfolio developments and licensing opportunities could uplift long-term valuations.